Literature DB >> 17940725

Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy.

R Bauer1, J Dobesberger, C Unterhofer, I Unterberger, G Walser, G Bauer, E Trinka, M Ortler.   

Abstract

BACKGROUND: Tumours are a well-recognized cause of medically intractable epilepsies. Tumours represent the primary pathology in 10%-30% of patients undergoing surgical treatment for chronic epilepsy. This study examines the surgical and epileptological outcome of adults with temporal lobe tumoural epilepsy treated within a comprehensive epilepsy surgery programme.
METHODS: Between 1999 and 2004, 99 consecutive patients have been operated for intractable temporal lobe epilepsy (TLE). Among these, 14 adult patients exhibited temporal lobe neoplasms associated with TLE. Every patient underwent a comprehensive presurgical evaluation including video-EEG monitoring, MRI, interictal PET scan, ictal SPECT and neuropsychological testing. Surgical strategies were determined in an interdisciplinary seizure conference and tailored to the findings of the presurgical evaluation. All patients were available for follow up at regular intervals after 3, 6, 12 months and yearly thereafter. Epileptological outcome was classified according to Engel [10] and the ILAE (International League Against Epilepsy)/systems [33].
FINDINGS: The surgical procedures performed were temporal lobe resection in 3 patients, extended lesionectomy in 4 and extended lesionectomy with resection of the temporomesial structures in 7. One patient with an astrocytoma grade III underwent a second and third operation for recurrent disease. Histological results: Astrocytoma 5 patients, ganglioglioma/gangliocytoma 5, oligodendroglioma 2, ependymoma 1 and dysembryoplastic neuroepithelial tumour (DNET) 1. Postoperative follow-up was performed after 12-74 months (mean 31). The outcome according to the Engel classification indicated class IA in 9 patients, class IC in 3, and 1 each in classes IIIA and IVA. Epileptological outcome according to the ILAE classification indicated class 1 (12 patients) and class 4 (2 patients). Surgical mortality was zero and mild permanent neurological deficits due to surgery were seen in 2 patients. Postoperatively 3 patients showed a homonymous quadrantanopia.
CONCLUSIONS: Patients with drug resistant epilepsy and temporal lobe tumours should undergo evaluation in dedicated epilepsy surgery programmes.

Entities:  

Mesh:

Year:  2007        PMID: 17940725     DOI: 10.1007/s00701-007-1366-z

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  Surgery for epilepsy.

Authors:  Siobhan West; Sarah J Nevitt; Jennifer Cotton; Sacha Gandhi; Jennifer Weston; Ajay Sudan; Roberto Ramirez; Richard Newton
Journal:  Cochrane Database Syst Rev       Date:  2019-06-25

Review 2.  Treatment of epileptic seizures in brain tumors: a critical review.

Authors:  R Bauer; M Ortler; M Seiz-Rosenhagen; R Maier; J V Anton; I Unterberger
Journal:  Neurosurg Rev       Date:  2014-04-24       Impact factor: 3.042

Review 3.  Epilepsy associated tumors: Review article.

Authors:  Marco Giulioni; Gianluca Marucci; Matteo Martinoni; Anna Federica Marliani; Francesco Toni; Fiorina Bartiromo; Lilia Volpi; Patrizia Riguzzi; Francesca Bisulli; Ilaria Naldi; Roberto Michelucci; Agostino Baruzzi; Paolo Tinuper; Guido Rubboli
Journal:  World J Clin Cases       Date:  2014-11-16       Impact factor: 1.337

Review 4.  Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments.

Authors:  Roberta Rudà; Lorenzo Bello; Hugues Duffau; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

5.  Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis.

Authors:  Xia Shan; Xing Fan; Xing Liu; Zheng Zhao; Yinyan Wang; Tao Jiang
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.